Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Janux Therapeutics, Inc. - Common Stock (NQ:JANX)

23.56 -0.49 (-2.04%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 553,280
Open 24.23
Bid (Size) 23.40 (1)
Ask (Size) 24.98 (1)
Prev. Close 24.05
Today's Range 23.32 - 24.23
52wk Range 21.97 - 71.71
Shares Outstanding 41,833,315
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Janux (JANX) R&D Soars Revenue Misses
Via The Motley Fool
Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire

Performance

YTD
-55.7%
-55.7%
1 Month
-6.2%
-6.2%
3 Month
-0.2%
-0.2%
6 Month
-25.2%
-25.2%
1 Year
-52.8%
-52.8%

More News

Read More
Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck
From Janux Therapeutics
Via Business Wire
Navigating 10 Analyst Ratings For Janux Therapeutics
Via Benzinga
Why Janux Therapeutics Crushed the Market Today
Via The Motley Fool
Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day
From Janux Therapeutics
Via Business Wire
Janux Therapeutics to Host Virtual R&D Day on July 24, 2025
From Janux Therapeutics
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
The Top 5 Mid Cap Stocks Of 2024
Via Talk Markets
Topics Stocks / Equities
SoundHound, Asana And Victorias Secret Are Among Top 10 Mid Cap Gainers Last Week (Dec 2-Dec 6): Are The Others In Your Portfolio?
Via Benzinga
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From Janux Therapeutics
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Janux Therapeutics Announces Proposed Public Offering
From Janux Therapeutics
Via Business Wire
S&P 500 Cools From Post-Election Record Highs
Via Talk Markets
Topics Stocks Stocks / Equities
Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst
Via Benzinga
AT&T Updates 2024 Outlook, Joins ZJK Industrial, Janux Therapeutics, Credo Technology Group And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients
Via Investor's Business Daily
Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC
From Janux Therapeutics
Via Business Wire

Frequently Asked Questions

Is Janux Therapeutics, Inc. - Common Stock publicly traded?
Yes, Janux Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Janux Therapeutics, Inc. - Common Stock trade on?
Janux Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Janux Therapeutics, Inc. - Common Stock?
The ticker symbol for Janux Therapeutics, Inc. - Common Stock is JANX on the Nasdaq Stock Market
What is the current price of Janux Therapeutics, Inc. - Common Stock?
The current price of Janux Therapeutics, Inc. - Common Stock is 23.56
When was Janux Therapeutics, Inc. - Common Stock last traded?
The last trade of Janux Therapeutics, Inc. - Common Stock was at 09/15/25 04:00 PM ET
What is the market capitalization of Janux Therapeutics, Inc. - Common Stock?
The market capitalization of Janux Therapeutics, Inc. - Common Stock is 985.59M
How many shares of Janux Therapeutics, Inc. - Common Stock are outstanding?
Janux Therapeutics, Inc. - Common Stock has 986M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.